Navigation Links
Vion Pharmaceuticals to Present at 20th Annual Bear Stearns Healthcare Conference
Date:9/10/2007

is news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Annual Report on Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended June 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of subsequent events, Vion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

COMPANY CONTACT: Vion Pharmaceuticals, Inc.

Alan Kessman, Chief Executive Officer

Howard B. Johnson, President & CFO

(203)498-4210


'/>"/>
SOURCE Vion Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... , Jan. 14, 2014 As pet owners drew up ... many of them wrote: "Take better care of my furry companion." ... designer clothes and top-brand carrying cases to take the little canine ... might also feel compelled to buy some pricey toys at the ...
(Date:1/14/2014)... Toronto, Canada (PRWEB) January 14, 2014 ... and its motives and methods in product development and ... of the industry. This mistrust, fueled by concerns about ... further fed by reports of spectacular fines to the ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Kerr Corporation, a ... video and additional how-to information about dual arch impressions on ... with Dual Arch Impressions,” the blog entry serves up a ... and houses a step-by-step demonstration by Dr. David Little as ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... Md., Jan. 26 Novavax, Inc. (Nasdaq:, NVAX ... Good Manufacturing,Practice ("GMP") Pilot Plant to manufacture pandemic and ... 1,000 liter scale are,installed and ready for operations supporting ... project was initiated in December 2007. The facility ...
... Inc., a leading provider of enterprise-wide software and ... announced it has entered into a partner referral ... Alcoholism and Substance Abuse Providers (ASAP) for Netsmart ... learning management solution. ASAP is a not-for-profit membership ...
... Battelle for submission of proposals to U.S. Government ... Medical Corporation (OTC Bulletin Board: CONX), a worldwide ... announced a collaboration with Battelle, a Columbus, Ohio-based ... includes national security. Under the collaboration, Corgenix will ...
Cached Biology Technology:Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility 2Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility 3Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility 4Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 2Netsmart University Announces Partner Referral Agreement With New York Association of Alcohol and Substance Abuse Providers 3Corgenix Signs Collaboration With Battelle 2Corgenix Signs Collaboration With Battelle 3
(Date:4/24/2014)... Ludwig-Maximilians-Universitaet (LMU) in Munich have identified the structural ... discriminate between viral and endogenous RNAs in living ... control of cellular metabolism and hijack cellular resources ... is dependent on viral RNA molecules that are ... viruses) and/or newly synthesized in the host cell, ...
(Date:4/24/2014)... State University and the University of North Carolina at ... could help identify arterial plaque that is at high ... stroke. , At issue is the plaque that builds ... plaque are deemed "vulnerable," meaning that they are more ... heart attack or stroke. , "Existing state-of-the-art technologies are ...
(Date:4/24/2014)... river turtle in North America, weighing in at up ... researchers from Florida and the University of Vermont have ... three. , Examining museum specimens and wild turtles, the ... , Once heavily hunted for turtle meat alligator ... in the 1960s the riverine populations have been ...
Breaking Biology News(10 mins):Viral infections: Identifying the tell-tale patterns 2Viral infections: Identifying the tell-tale patterns 3New ultrasound device may add in detecting risk for heart attack, stroke 2Two new US turtle species described 2Two new US turtle species described 3
... greater role in the disparity between the numbers of ... with the disease. A study by researchers at the ... the disparity was substantially reduced when comparing groups of ... environments. The results are published in the November 2008 ...
... RELEASE LEDs ... Chemical Society Researchers in Germany are describing a ... facial wrinkles. Their study, scheduled for the November 5 ... a bi-monthly journal, reports that high intensity visible light ...
... amyloid-b (Ab), builds up into fibrous plaques in the ... membrane microdomain to another to be cleaved, report Sakurai ... that Ab plaques are the direct cause of Alzheimer,s ... And working on this hypothesis, scientists are investigating just ...
Cached Biology News:Hypertension disparity linked to environment 2American Chemical Society Weekly PressPac Oct. 15, 2008 2American Chemical Society Weekly PressPac Oct. 15, 2008 3American Chemical Society Weekly PressPac Oct. 15, 2008 4American Chemical Society Weekly PressPac Oct. 15, 2008 5American Chemical Society Weekly PressPac Oct. 15, 2008 6American Chemical Society Weekly PressPac Oct. 15, 2008 7American Chemical Society Weekly PressPac Oct. 15, 2008 8
... state-of-the-art separation system using the asymmetric flow ... integrates easily with Wyatts multi-angle light scattering ... as the Optilab DSP. The combined system ... of the particles/molecules separated by the AFFF ...
Monoclonal antibodies conjugated with rhodamine...
... compact and lightweight, the Moticam 2300 camera ... the eyepiece, eyetube, or trinocular port. Included ... use Plug-and-Play Images 2.0ML software offers quick ... tools to maximize resolution for examination or ...
5X StabilCoat Immunoassay Stabilizer is a 5X concentrate solution of StabilCoat Immunoassay Stabilizer. The shelf-life of 5X StabilCoat Immunoassay Stabilizer is 2 years when stored at 4C. Product ...
Biology Products: